FDA to re­con­sid­er re­moval of Lil­ly's GLP-1 drug from short­age list, a win for com­pound­ing phar­ma­cies

The FDA said it will re­con­sid­er the re­moval of Eli Lil­ly’s GLP-1 drug tirzepatide from its of­fi­cial short­age list, af­ter a trade group rep­re­sent­ing large …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA